Breaking News

Samsung Invests $10M in CS2 Diagnostics

Bolsters C2N’s ability to further scale its clinical laboratory services and advanced diagnostic solutions in the field of brain health.

Author Image

By: Charlie Sternberg

Associate Editor

C2N Diagnostics, LLC, a specialty diagnostics company, has received a $10 million investment from Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment Corporation—bolstering its ability to further scale its clinical laboratory services and advanced diagnostic solutions in the field of brain health. Dr. Joel Braunstein, CEO of C2N, said, “Samsung is an international leader and widely recognized for the seriousness and thorough reviews it undertakes in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters